Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus-specific B-cell receptors (HBV-BCRs) are membrane-bound immunoglobulins on the surface of B lymphocytes that recognize and bind to specific epitopes of the Hepatitis B virus, including the surface antigen (HBsAg), core antigen (HBcAg), and viral polymerase [1, 2]. These receptors are essential for the initiation of the humoral immune response, as their engagement by viral antigens triggers B-cell activation, clonal expansion, and differentiation into antibody-secreting plasma cells or memory B cells [3, 4]. In patients with chronic hepatitis B (CHB), HBsAg-specific BCRs frequently exhibit a state of functional exhaustion or an "atypical" memory phenotype, characterized by the expression of inhibitory receptors such as PD-1 and a failure to produce sufficient neutralizing antibodies [1, 2, 4]. In contrast, HBcAg-specific BCRs often remain more functional and are found at higher frequencies in the circulation [3]. Therapeutic strategies currently under investigation aim to modulate these receptors through therapeutic vaccines like VBI-2601 (BRII-179) to restore B-cell function or by utilizing high-affinity BCR sequences to develop monoclonal antibodies such as VIR-3434 for passive immunotherapy [4, 6]. Understanding the specificity and functionality of the HBV-BCR repertoire is a key component in the pursuit of a functional cure for chronic HBV infection [3]. [1] Salimzadeh, L., et al. (2018). Journal of Experimental Medicine. [2] Burton, A. R., et al. (2018). Journal of Clinical Investigation. [3] Le Bert, N., et al. (2020). Gastroenterology. [4] Poonia, B., et al. (2020). Seminars in Immunopathology. [5] Weimer, T., et al. (1990). Journal of Virology. [6] Gane, E., et al. (2021). VIR-3434 Clinical Data.
Binding of HBV antigens to the BCR triggers B-cell activation, antigen internalization, and presentation to T cells, leading to the production of neutralizing antibodies and the establishment of immunological memory.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus-specific B-cell receptor (HBV-BCR) (HBV-BCR).